News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
An investor group comprising Perceptive Advisors LLC, Joseph Edelman, and Perceptive Life Sciences Master Fund, Ltd. has reported a beneficial ownership of 9.99% in Alto Neuroscience (ANRO). This ownership, totaling 4,176,711 shares, includes common stock and pre-funded warrants, with the exercise of warrants capped …
Vestal Point Capital, LP and Ryan Wilder have filed an amended Schedule 13G, disclosing a 2.2% beneficial ownership in Alto Neuroscience, Inc., totaling 785,000 shares. These shares are held through a fund and a managed account advised by Vestal Point Capital, with both shared …
Alto Neuroscience, Inc. (ANRO) has seen its average 12-month price target increased to $37.56 by 9 analysts, suggesting a 16% potential upside from its August 13 closing price. The consensus rating for the stock remains a "Buy" from 11 analysts.
Two healthcare companies, Alto Neuroscience, Inc. (ANRO) and Owlet (OWLT), recently received bullish ratings from analysts. Myles Minter from William Blair reiterated a Buy rating for Alto Neuroscience, with a consensus price target of $35.71. Jonna Kim from TD Cowen also reiterated a Buy …
Alto Neuroscience Inc. (ANRO) stock has reached an all-time high of $32.74, marking a 906.09% increase over the past year. Despite this surge, InvestingPro suggests the stock may be overvalued. The company recently announced a stock offering to raise $100 million, received a reiterated …
Wedbush has increased its price target for Alto Neuroscience from $24 to $26, while maintaining a Neutral rating on the stock. The article also briefly mentions Unity Software's fourth-quarter financial results, including a 35% year-over-year revenue increase to $609 million and a quarterly loss …
Alto Neuroscience (NYSE:ANRO) shares rose 8% after reporting a quarterly loss of $0.65 per share, surpassing the consensus estimate of a $0.73 loss. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $36.62, and institutional investors like Commodore Capital and …
Alto Neuroscience (NYSE: ANRO) reported a Q2 2026 EPS of $(0.65), exceeding analyst estimates of $(0.73). The company also completed a $100 million financing round in July 2026, boosting its pro forma cash position to approximately $338 million, which is expected to fund operations …
Alto Neuroscience (ANRO) reported a net loss of $27.6 million for Q2 2026, widening from the previous year, primarily due to increased R&D expenses which surged to $22.1 million. Despite the loss, the company significantly strengthened its balance sheet, increasing cash and cash equivalents …
Alto Neuroscience (ANRO) reported a net loss of $27.6 million for Q2 2026, an increase from $17.7 million a year prior, while also announcing the expansion of its ALTO-207 program with plans for an additional Phase 3 trial in treatment-resistant depression. The company secured …
This article provides an earnings forecast for Alto Neuroscience Inc (ANRO), detailing analyst ratings and EPS expectations. Ten analysts currently rate ANRO as a "Strong Buy" with a target price indicating a potential 24.11% upside. The previous quarter's EPS was -$0.47, beating the market …
Alto Neuroscience Inc. (ANRO) stock reached an all-time high of $29.34 and currently trades at $29.10, near its 52-week high, with a market capitalization of $1.09 billion. The stock has surged 840.52% in the past year, reflecting strong investor confidence despite being unprofitable according …
Levi & Korsinsky LLP has filed a class action lawsuit against Alto Neuroscience, Inc. (ANRO) on behalf of investors who suffered losses. The lawsuit alleges that Alto Neuroscience made false and misleading statements regarding the effectiveness of its product pipeline, ALTO-100, for treating major …
Eleven analysts have given Alto Neuroscience, Inc. (NYSE:ANRO) a consensus "Moderate Buy" rating, with eight recommending a buy, two a sell, and one a hold. The average 12-month price target is $35.25, significantly higher than its opening price of $27.09. Despite increased institutional investment …
BlackRock, Inc. has reported a 6.0% beneficial ownership in Alto Neuroscience Inc. common stock, holding 2,104,406 shares. The investment firm has sole voting power over 2,077,542 shares and sole dispositive power over all 2,104,406 shares, with no single underlying client holding more than five …
This article provides a detailed company profile for Alto Neuroscience Inc (ANRO), focusing on its business scope, financial data, and market performance. It highlights the company's clinical-stage biopharmaceutical focus on personalized psychiatric treatments using its Precision Psychiatry Platform and lists key executives and major …
This article provides a technical analysis of Alto Neuroscience Inc (ANRO), focusing on support, resistance, indicators, and moving averages. It details various technical indicators like MACD, RSI, and KDJ, along with their values and directions, and analyzes moving averages from MA5 to MA200. The …
This article details the shareholder structure of Alto Neuroscience Inc (ANRO), listing its major individual and institutional holders and their respective proportions. It also presents a breakdown of shareholder types, institutional shareholding over several quarters, and related ETF holdings. The data provides insight into …
This article from TradingKey provides an overview of institutional confidence in Alto Neuroscience Inc (ANRO). It details key institutional shareholders, the number of shares held, and the change in their holdings. The report highlights firms like Alpha Wave Global, LP and Vestal Point Capital, …
This article from TradingView provides a financial overview of Alto Neuroscience, Inc. (NYSE: ANRO), focusing on its revenue breakdown. It lists various sections available on the TradingView platform for detailed financial analysis, including statements, statistics, dividends, earnings, and segment performance. The content primarily serves …
EcoR1 Capital, along with its control person Oleg Nodelman, has reported a 5.8% beneficial ownership in Alto Neuroscience (ANRO), amounting to 2,232,000 shares. The disclosure was made via a Schedule 13G filing, indicating that the securities were acquired for investment purposes without the intent …
Search by ticker symbol or company name and select a result to open its chart.